Certara Launches Secondary Intelligence™ Software to Predict Risk of Unwanted Side Effects of Drug Candidates Earlier

First-of-its-kind software predicts likelihood of off-target safety issues that could impede clinical progress PRINCETON, NJ – May 4, 2021, Certara, Inc. (Nasdaq: CERT), the global leader in biosimulation, today announced the launch of its Secondary Intelligence™ software, the first and only software that quantitatively predicts the risk of adverse effects and safety issues derived from … Continued

Certara Announces Closing of Public Offering of Common Stock

PRINCETON, N.J.– March 29, 2021 –Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the closing of its underwritten public offering of 11,500,000 shares of its common stock by certain existing stockholders at a public offering price of $25.00 per share. The closing includes 1,500,000 shares sold upon full exercise of the underwriters’ … Continued

Certara Announces Pricing of Public Offering of Common Stock

PRINCETON, N.J.—March 24, 2021. Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of 10 million shares of its common stock by certain existing stockholders (“the selling stockholders”) at a price to the public of $25.00 per share.  Additionally, the selling stockholders have granted the underwriters … Continued

Certara Announces Proposed Public Offering of Common Stock

PRINCETON, N.J.—March 22, 2021. Certara, Inc. (“Certara”), a global leader in biosimulation, today announced a proposed underwritten public offering of 17 million shares of its common stock being offered by selling stockholders.  Additionally, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to 2,550,000 additional shares of common stock. Certara … Continued

Certara Set to Join Russell 1000® Index

PRINCETON, N.J.—Mar. 11, 2021– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it is set to join the Russell 1000® Index, effective after the U.S. market open on March 22, 2021, according to a preliminary list of quarterly IPO additions posted February 26, 2021. The Russell 1000® Index measures the performance … Continued

Certara Reports Preliminary Fourth Quarter and Full Year 2020 Results and Issues Full Year 2021 Guidance

Year-over-year 2020 revenue grew 17% to $243.5 million Raised $768.5 million in gross IPO proceeds for the Company and selling stockholders PRINCETON, N.J.—Mar. 4, 2021– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its preliminary results for the fourth quarter and full year ended December 31, 2020. Highlights: Revenue was $64.6 million … Continued

Certara Acquires AUTHOR!, a Regulatory and Biostatistics Services Firm in Europe

Broadens European footprint with integrated regulatory services and statistical analysis PRINCETON, NJ.— March 2, 2021– Certara, Inc., a global leader in biosimulation, today announced the acquisition of AUTHOR!, a company that provides medical writing and statistical analysis of clinical trial data to global pharmaceutical and biotechnology companies.  Founded in 1998, AUTHOR! is based near Amsterdam … Continued

1 of 24
Back to top
Powered by Translations.com GlobalLink OneLink Software